Liu X - Search Results

1

Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.

Wang R, Li L, Duan A, Li Y, Liu X, Miao Q, Gong J, Zhen Y. Wang R, et al. Among authors: liu x. Cancer Lett. 2019 Apr 28;448:84-93. doi: 10.1016/j.canlet.2019.02.002. Epub 2019 Feb 8. Cancer Lett. 2019. PMID: 30742941

2

[Inhibitory effect of lidamycin on growth of colon carcinoma 26 and hepatic metastasis in mice].

Liu XJ, Dai Y, Shang Y, Li Y, Zhen YS. Liu XJ, et al. Ai Zheng. 2005 Jun;24(6):641-5. Ai Zheng. 2005. PMID: 15946470 Chinese.

3

[Antitumor effect of the novel immunoconjugate composed of pingyangmycin and anti-type IV collagenase monoclonal antibody].

Dai Y, Liu XJ, Zhen YS. Dai Y, et al. Yao Xue Xue Bao. 2006 Jan;41(1):41-6. Yao Xue Xue Bao. 2006. PMID: 16683526 Chinese.

4

[Rhein lysinate induces apoptosis in breast cancer SK-Br-3 cells by inhibiting HER-2 signal pathway].

Lin YJ, Huang YH, Zhen YZ, Liu XJ, Zhen YS. Lin YJ, et al. Yao Xue Xue Bao. 2008 Nov;43(11):1099-105. Yao Xue Xue Bao. 2008. PMID: 19239027 Chinese.

5

Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.

Liu H, Li L, Li XQ, Liu XJ, Zhen YS. Liu H, et al. Anticancer Drugs. 2009 Jan;20(1):41-9. doi: 10.1097/CAD.0b013e328318292c. Anticancer Drugs. 2009. PMID: 19342999

6

A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice.

Zhong G, Zhang S, Li Y, Liu X, Gao R, Miao Q, Zhen Y. Zhong G, et al. Among authors: liu x. Cancer Lett. 2010 Sep 1;295(1):124-33. doi: 10.1016/j.canlet.2010.02.020. Epub 2010 Mar 19. Cancer Lett. 2010. PMID: 20303650

7

HERG K+ channel related chemosensitivity to sparfloxacin in colon cancer cells.

Gong JH, Liu XJ, Shang BY, Chen SZ, Zhen YS. Gong JH, et al. Oncol Rep. 2010 Jun;23(6):1747-56. doi: 10.3892/or_00000820. Oncol Rep. 2010. PMID: 20428834

8

Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy.

Zhang Q, Liu XJ, Hu L, Liao DS, Zheng YB, Zhen YS, Song X. Zhang Q, et al. Among authors: liu xj. Int J Mol Med. 2012 Mar;29(3):409-15. doi: 10.3892/ijmm.2011.848. Epub 2011 Nov 22. Int J Mol Med. 2012. PMID: 22108624

9

Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.

Gong JH, Liu XJ, Li Y, Zhen YS. Gong JH, et al. Cancer Chemother Pharmacol. 2012 May;69(5):1323-32. doi: 10.1007/s00280-012-1827-9. Epub 2012 Feb 5. Cancer Chemother Pharmacol. 2012. PMID: 22311160

10

Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.

Zhen YZ, Lin YJ, Liu XJ, Shang BY, Zhen YS. Zhen YZ, et al. Anticancer Drugs. 2013 Jul;24(6):609-16. doi: 10.1097/CAD.0b013e3283615006. Anticancer Drugs. 2013. PMID: 23698252

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

136,416 results

Search Page

Filters